- Home
- ELAB vs RNAZ Comparison
ELAB vs RNAZ Comparison
Compare ELAB & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- RNAZ
- Stock Information
- Founded
- ELAB 2020
- RNAZ 2016
- Country
- ELAB United States
- RNAZ United States
- Employees
- ELAB N/A
- RNAZ N/A
- Industry
- ELAB
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- RNAZ Health Care
- Exchange
- ELAB Nasdaq
- RNAZ Nasdaq
- Market Cap
- ELAB 6.6M
- RNAZ 6.1M
- IPO Year
- ELAB 2023
- RNAZ 2021
- Fundamental
- Price
- ELAB $2.16
- RNAZ $7.97
- Analyst Decision
- ELAB
- RNAZ Strong Buy
- Analyst Count
- ELAB 0
- RNAZ 1
- Target Price
- ELAB N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- ELAB 1.5M
- RNAZ 32.8K
- Earning Date
- ELAB 08-13-2025
- RNAZ 08-13-2025
- Dividend Yield
- ELAB N/A
- RNAZ N/A
- EPS Growth
- ELAB N/A
- RNAZ N/A
- EPS
- ELAB N/A
- RNAZ N/A
- Revenue
- ELAB N/A
- RNAZ N/A
- Revenue This Year
- ELAB N/A
- RNAZ N/A
- Revenue Next Year
- ELAB N/A
- RNAZ N/A
- P/E Ratio
- ELAB N/A
- RNAZ N/A
- Revenue Growth
- ELAB N/A
- RNAZ N/A
- 52 Week Low
- ELAB $1.95
- RNAZ $6.15
- 52 Week High
- ELAB $840.00
- RNAZ $970.20
- Technical
- Relative Strength Index (RSI)
- ELAB 45.40
- RNAZ 47.04
- Support Level
- ELAB $1.96
- RNAZ $7.32
- Resistance Level
- ELAB $2.26
- RNAZ $8.48
- Average True Range (ATR)
- ELAB 0.22
- RNAZ 0.58
- MACD
- ELAB 0.03
- RNAZ 0.41
- Stochastic Oscillator
- ELAB 17.95
- RNAZ 70.77
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.